Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 9/20 | 0.89 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.89 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.56 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936678 | 1.00 | TLR9 (0.89) | TLR9TLR7KMT5AEHMT2PDGFRB | |
| SCHEMBL19405156 | 0.89 | TLR9 (0.80) | TLR9TLR7PDGFRBKIT | |
| SCHEMBL19405217 | 0.87 | TLR9 (0.76) | TLR9TLR7EHMT2PDGFRBKIT | |
| SCHEMBL19385098 | 0.87 | TLR9 (1.00) | TLR9TLR7PDGFRB | |
| SCHEMBL23726611 | 0.87 | TLR9 (0.71) | TLR9TLR7PDGFRBKIT | |
| SCHEMBL30080195 | 0.87 | TLR9 (0.71) | TLR9TLR7PDGFRBKIT | |
| SCHEMBL2918088 | 0.86 | TLR9 (0.76) | TLR9TLR7PDGFRBKIT | |
| SCHEMBL19385275 | 0.86 | TLR9 (0.67) | TLR9TLR7KMT5AEHMT2 | |
| SCHEMBL19405154 | 0.86 | TLR9 (0.67) | TLR9TLR7KMT5AEHMT2PDGFRB | |
| SCHEMBL19385115 | 0.84 | TLR7 (0.67) | TLR9TLR7KMT5AEHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662177-B2 | Blocking toll-like receptor 9 signaling with small molecule antagonist | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-05-26 | — | — | US | disclosed |
| US-10662177-B2 | Blocking toll-like receptor 9 signaling with small molecule antagonist | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-05-26 | — | — | US | disclosed |
| US-20190092758-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-03-28 | — | — | US | disclosed |
| US-20190092758-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-03-28 | — | — | US | disclosed |
| EP-3433249-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | Council Of Scientific & Industrial Research (IN) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017163264-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017163264-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092758-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | TLR9, TLR1, TLR3 | TLR9 1/4885TLR7 5/4885KMT5A 2084/4885 |
| US-10662177-B2 | Blocking toll-like receptor 9 signaling with small molecule antagonist | TLR9, TLR1, TLR3 | TLR9 1/4885TLR7 4/4885KMT5A 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.